<div class="infobox infobox-protein">
| | |
|---|---|
| Protein Name | Sphingosine-1-Phosphate Receptor 1 (S1PR1) |
| Gene | [S1PR1](/genes/s1pr1) |
| UniProt ID | [P21453](https://www.uniprot.org/uniprot/P21453) |
| Molecular Weight | ~43 kDa (382 amino acids) |
| Subcellular Localization | Plasma membrane |
| Protein Family | G protein-coupled receptor family (S1PR1-5) |
| Chromosomal Location | 1p21 |
| Brain Expression | Neurons, astrocytes, microglia, oligodendrocytes |
</div>
Sphingosine-1-Phosphate Receptor 1 (S1PR1) is a G protein-coupled receptor (GPCR) that binds the bioactive lipid sphingosine-1-phosphate (S1P). S1PR1 is the founding member of a family of five S1P receptors (S1PR1-5) that are widely expressed throughout the body and regulate diverse physiological processes including immune cell trafficking, vascular development, and neural function[@chun2006][@cyster2014].
S1PR1 couples primarily to Gi/o proteins, leading to activation of downstream signaling pathways including PI3K/Akt, MAPK/ERK, and Rac GTPases. This signaling regulates cell survival, proliferation, migration, and cytokine production. In the immune system, S1PR1 is essential for lymphocyte egress from secondary lymphoid organs—a function that underlies the therapeutic efficacy of S1PR1 modulators in multiple sclerosis[@signaling2023].
<div class="infobox infobox-protein">
| | |
|---|---|
| Protein Name | Sphingosine-1-Phosphate Receptor 1 (S1PR1) |
| Gene | [S1PR1](/genes/s1pr1) |
| UniProt ID | [P21453](https://www.uniprot.org/uniprot/P21453) |
| Molecular Weight | ~43 kDa (382 amino acids) |
| Subcellular Localization | Plasma membrane |
| Protein Family | G protein-coupled receptor family (S1PR1-5) |
| Chromosomal Location | 1p21 |
| Brain Expression | Neurons, astrocytes, microglia, oligodendrocytes |
</div>
Sphingosine-1-Phosphate Receptor 1 (S1PR1) is a G protein-coupled receptor (GPCR) that binds the bioactive lipid sphingosine-1-phosphate (S1P). S1PR1 is the founding member of a family of five S1P receptors (S1PR1-5) that are widely expressed throughout the body and regulate diverse physiological processes including immune cell trafficking, vascular development, and neural function[@chun2006][@cyster2014].
S1PR1 couples primarily to Gi/o proteins, leading to activation of downstream signaling pathways including PI3K/Akt, MAPK/ERK, and Rac GTPases. This signaling regulates cell survival, proliferation, migration, and cytokine production. In the immune system, S1PR1 is essential for lymphocyte egress from secondary lymphoid organs—a function that underlies the therapeutic efficacy of S1PR1 modulators in multiple sclerosis[@signaling2023].
In the central nervous system, S1PR1 is expressed on neurons, astrocytes, microglia, and oligodendrocyte progenitor cells. Here it modulates neurogenesis, myelination, synaptic function, and neuroinflammatory responses. S1PR1 modulators like fingolimod (FTY720), siponimod, and ozanimod are approved for treating multiple sclerosis, and extensive research explores their potential in other neurodegenerative conditions[@fty2022][@spr2023].
The human S1PR1 gene is located on chromosome 1p21 and encodes a 382-amino acid protein. The gene consists of 6 exons and is approximately 10 kb in length. The gene is evolutionarily conserved across vertebrates.
S1PR1 is a classic GPCR with seven transmembrane helices:
N-terminal Extracellular Domain (aa 1-50): Contains glycosylation sites and contributes to ligand binding pocket. The extracellular loops (ECL1-3) between transmembrane helices also participate in S1P binding.
Transmembrane Domain (aa 51-310): Seven α-helices (TM1-7) connected by intracellular and extracellular loops. This domain contains:
S1PR1 undergoes several modifications:
S1PR1's best-characterized function is regulating lymphocyte egress:
Lymphocyte Egress: S1P concentration gradients guide lymphocytes from lymphoid organs into lymph and blood. S1PR1 on mature T and B cells responds to high systemic S1P, enabling their exit.
T Cell Trafficking: Naive T cells express S1PR1 and require it for exit from lymph nodes. Memory T cells use S1PR1 for recirculation.
B Cell Trafficking: B cells also require S1PR1 for follicular exit and subsequent migration.
Dendritic Cell Migration: S1PR1 regulates dendritic cell trafficking to lymph nodes.
S1PR1 is essential for vascular formation:
Angiogenesis: S1P signaling through S1PR1 promotes blood vessel formation and stabilization.
Vascular Maturation: S1PR1 on endothelial cells interacts with pericytes to stabilize vessels.
Vascular Integrity: S1PR1 maintains endothelial barrier function.
In the CNS, S1PR1 has multiple roles:
Neurogenesis: S1PR1 regulates neural progenitor cell proliferation and migration in the subventricular zone and dentate gyrus.
Myelination: S1PR1 influences oligodendrocyte differentiation and myelination. Both S1P and S1PR1 are required for proper myelin formation.
Synaptic Function: S1PR1 is expressed at synapses and modulates synaptic transmission and plasticity.
Astrocyte Function: S1PR1 regulates astrocyte morphology and function.
Microglial Activation: S1PR1 modulates microglial activation states and neuroinflammatory responses.
S1PR1 exhibits region-specific expression:
At the cellular level:
S1PR1 is a validated therapeutic target in multiple sclerosis:
FTY720 (Fingolimod): First oral disease-modifying therapy for MS, approved in 2010. Works primarily through S1PR1 modulation.
Siponimod (BAF312): S1PR1 and S1PR5 selective modulator, approved for secondary progressive MS.
Ozanimod: S1PR1 and S1PR5 selective, approved for relapsing forms of MS.
Ponesimod: S1PR1 selective, approved for relapsing forms of MS.
S1PR1 modulators work through multiple mechanisms:
Lymphocyte Sequestration: By acting as functional antagonists at S1PR1, these drugs prevent lymphocyte egress from lymph nodes. This reduces autoreactive T and B cells entering the CNS.
Direct CNS Effects: S1PR1 modulators also act on CNS cells:
Clinical trials show:
S1PR1 alterations have been reported in Alzheimer's disease:
Expression Changes: S1PR1 expression is altered in AD brains, with some studies showing increased expression in affected regions.
Genetic Studies: Some S1PR1 variants have been associated with AD risk, though data are not as extensive as for other genes.
Therapeutic Potential: S1PR1 modulators may have benefits in AD through:
Microglial Modulation: S1PR1 regulates microglial activation states. S1PR1 modulation may shift microglia toward protective phenotypes.
Neuroinflammation: S1PR1 signaling influences inflammatory cytokine production and immune cell infiltration.
Astrogliosis: S1PR1 affects astrocyte reactivity, which is prominent in AD.
Synaptic Function: S1PR1 modulation may protect synapses from inflammatory damage.
Limited evidence links S1PR1 to Parkinson's disease:
Expression Changes: Some studies show altered S1P signaling in PD models and patient tissue.
Therapeutic Potential: S1PR1 modulators may provide benefits through:
Dopaminergic Neuron Survival: S1PR1 signaling promotes neuronal survival in models of dopaminergic degeneration.
Neuroinflammation: S1PR1 modulates microglial activation relevant to PD pathogenesis.
Mitochondrial Function: S1P signaling affects mitochondrial dynamics and function.
S1PR1 modulation is protective in stroke models:
FTY720 Protection: FTY720 reduces infarct size and improves functional outcomes in animal models of ischemic stroke.
Anti-inflammatory: Reduced post-ischemic inflammation.
Neuroprotection: Direct protective effects on neurons.
Vascular Effects: May improve blood flow to ischemic penumbra.
Lymphocyte Effects: Reduced infiltration of inflammatory cells.
| Partner | Interaction Type | Functional Role |
|---------|-----------------|-----------------|
| S1P (sphingosine-1-phosphate) | Ligand binding | Receptor activation |
| Gi/o proteins | G protein coupling | Signal transduction |
| β-arrestin | Adapter protein | Receptor internalization |
| GRK | Kinase | Phosphorylation/desensitization |
| RGS proteins | GAP activity | Signal termination |
| S1PR5 | Receptor heterodimerization | Functional interaction |
S1PR1 activates multiple downstream cascades:
Gi/o Pathways:
Phenotype: S1pr1⁻/⁻ mice show:
Neural-specific deletion: Show alterations in neurogenesis and myelination.
Astrocyte-specific deletion: Reveal role in astrocyte function.
EAE (MS model): S1PR1 modulators are highly effective.
Stroke models: FTY720 reduces damage.
AD models: Mixed results—some benefit, some concerns.
Fingolimod (FTY720):
Study of S1PR1 employs various approaches: